The test rate (percentage tested of patients diagnosed with non-squamous cell carcinoma NSCLC) for EGFR has increased significantly (p < 0.001) over the analysed time period and has reached a plateau in recent years, being 59% in 2013 and 85% in 2020 (Figure 1). This evidence concerns the gene EGFR and non-small cell lung carcinoma.